<?xml version='1.0' encoding='utf-8'?>
<document id="27406945"><sentence text="No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies."><entity charOffset="21-33" id="DDI-PubMed.27406945.s1.e0" text="Ketoconazole" /></sentence><sentence text="In July 2013 the U" /><sentence text="S" /><sentence text=" Food and Drug Administration (FDA) released a safety announcement regarding the use of ketoconazole and its adverse drug reactions"><entity charOffset="88-100" id="DDI-PubMed.27406945.s4.e0" text="ketoconazole" /></sentence><sentence text=" The FDA report advised against the use ketoconazole tablets as a first-line treatment for any fungal infections because of the risk of potentially serious drug-drug interactions and liver and adrenal gland complications"><entity charOffset="40-52" id="DDI-PubMed.27406945.s5.e0" text="ketoconazole" /></sentence><sentence text=" The European Medicines Agency (EMA) also proposed to limit the use of oral ketoconazole in fungal infections because of the same risk of harmful effects and interactions"><entity charOffset="76-88" id="DDI-PubMed.27406945.s6.e0" text="ketoconazole" /></sentence><sentence text=" In addition, the FDA also advised against the use of oral ketoconazole in drug interaction studies, in which it has been extensively used as an index inhibitor of drug metabolism"><entity charOffset="59-71" id="DDI-PubMed.27406945.s7.e0" text="ketoconazole" /></sentence><sentence text=" The aim of this investigation was to evaluate the risks of ketoconazole-induced hepatotoxicity described by the FDA and EMA in published drug interaction studies with ketoconazole and compare these data with the toxicity reported for ketoconazole when used as antifungal treatment"><entity charOffset="60-72" id="DDI-PubMed.27406945.s8.e0" text="ketoconazole" /><entity charOffset="168-180" id="DDI-PubMed.27406945.s8.e1" text="ketoconazole" /><entity charOffset="235-247" id="DDI-PubMed.27406945.s8.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.27406945.s8.e0" e2="DDI-PubMed.27406945.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27406945.s8.e0" e2="DDI-PubMed.27406945.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27406945.s8.e0" e2="DDI-PubMed.27406945.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27406945.s8.e1" e2="DDI-PubMed.27406945.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27406945.s8.e1" e2="DDI-PubMed.27406945.s8.e2" /></sentence><sentence text=" In the drug interaction studies (2355 participants; healthy volunteers and patients; median treatment duration, 6 days), only 40 participants were reported to have increased liver transaminase activity (1" /><sentence text="7%), and no deaths were reported or associated with ketoconazole"><entity charOffset="52-64" id="DDI-PubMed.27406945.s10.e0" text="ketoconazole" /></sentence><sentence text=" In studies investigating ketoconazole treatment, patients were treated for 276 days (median), and 5"><entity charOffset="26-38" id="DDI-PubMed.27406945.s11.e0" text="ketoconazole" /></sentence><sentence text="6% of patients had elevated liver enzyme activity" /><sentence text=" Because of the short treatment period in drug interaction studies the risk of drug-induced hepatic injury is considered very low" /><sentence text=" As such, we recommend that ketoconazole remain a safe CYP3A index inhibitor for use in drug interaction studies with healthy volunteers"><entity charOffset="28-40" id="DDI-PubMed.27406945.s14.e0" text="ketoconazole" /></sentence><sentence text="" /></document>